4,217 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Todd Asset Management LLC

Todd Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, HoldingsChannel.com reports. The firm acquired 4,217 shares of the specialty pharmaceutical company’s stock, valued at approximately $556,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in JAZZ. Farther Finance Advisors LLC raised its holdings in Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 234 shares during the last quarter. Quent Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth $44,000. Hantz Financial Services Inc. raised its stake in shares of Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 297 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 30.7% during the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 154 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $166.31 on Tuesday. The stock has a market cap of $10.10 billion, a P/E ratio of -27.40, a P/E/G ratio of 0.89 and a beta of 0.26. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The stock’s fifty day moving average is $167.54 and its 200 day moving average is $147.79. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99.

Analysts Set New Price Targets

JAZZ has been the subject of several research analyst reports. UBS Group reiterated a “neutral” rating and issued a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. JPMorgan Chase & Co. lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Finally, Morgan Stanley reissued an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Fourteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $205.67.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 77,500 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the sale, the director directly owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This represents a 16.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the sale, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,813 shares of company stock valued at $15,564,549 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.